

M PHARMACEUTICAL TO OPEN A FULLY OWNED SUBSIDIARY IN SOFIA, BULGARIA

VANCOUVER, B.C., CANADA (18 August 2015) - **M Pharmaceutical, Inc.** (CSE:MQ, OTCQB: MPHMF, FWB:T3F2), (the "Company"), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological disorders, announced today that its Board of Directors has made a decision to open a fully owned subsidiary company M Pharma Bulgaria Ltd. with a clear mandate to achieve registration of the Company's temporary controllable pseudobezoar technology Trimeo as a medical device in the European Union, and to obtain a CE Mark for it. M Pharma Bulgaria will collaborate with Medica AD (Bulgaria), a leading producer of CE-certified medical materials in Eastern Europe, and with local vendors to achieve these objectives.

"Opening a subsidiary in Bulgaria, an European Union member state, demonstrates our commitment to quickly move towards registering Trimeo as a prescription-based medical device for the treatment of obesity in the European Union," said Dr. Martin Mintchev, the President and CEO of the Company. "We are confident that obtaining CE Mark for Trimeo and starting sales in Europe will strengthen our regulatory position with the U.S. Food and Drug Administration and Health Canada on our quest for subsequently entering the North American market."

For more information contact:

Investor Relations

Phone: +1 604 428 0511

info@m-pharma.ca

www.m-pharma.ca

About M Pharmaceutical Inc.

Formed in early 2015, **M Pharmaceutical Inc.** is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company has exclusive rights to three technologies: (1) **Trimeo** capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) **Trimtec**, gastrointestinal functional neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) **eMosquito** wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

About Medica AD (Bulgaria)

Medica AD (Bulgaria) is a leading manufacturer of CE-certified medical materials in Eastern Europe and has ISO-9001-2000¹ certificate of manufacturing quality audited by Lloyds' Register.

¹ ISO 9001:2000 specifies requirements for a quality management system where an organization needs to demonstrate its ability to consistently provide product that meets customer and applicable regulatory requirements; and aims to enhance customer satisfaction through the effective application of the system, including processes for continual improvement of the system and the assurance of conformity to customer and applicable regulatory requirements.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: Trimeo, Trimtec, and eMosquito are investigational devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.